Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.565 AUD | -0.88% | +8.65% | -31.93% |
05-21 | Transcript : Aroa Biosurgery Limited, 2024 Earnings Call, May 21, 2024 | |
05-21 | Aroa Biosurgery Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-31.93% | 130M | - | ||
+6.84% | 26.97B | B+ | ||
-40.08% | 2.67B | B- | ||
-19.95% | 2.4B | C+ | ||
+16.30% | 2.28B | B | ||
+7.28% | 2.24B | - | A- | |
-13.56% | 1.82B | - | ||
+16.67% | 1.79B | B | ||
+18.92% | 1.26B | B | ||
-2.24% | 1.21B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ARX Stock
- Ratings Aroa Biosurgery Limited